Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimitris Voliotis

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Seminars in Oncology|June 26, 2002
Challenges in treating hematologic malignanciesDimitris Voliotis, Volker Diehl
Anti-Cancer Drugs|January 19, 2005
The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell linesMartina Heim, Mariam Scharifi, Jochen Zisowsky, et al.
Gastrointestinal Cancer Research : GCR|June 16, 2011
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B CirrhosisGhassan K Abou-Alfa, Dino Amadori, Armando Santoro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumorsDirk Strumberg, Heike Richly, Ralf A Hilger, et al.
Journal of Hepatology|January 17, 2012
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalysesJean-Luc Raoul, Jordi Bruix, Tim F Greten, et al.
Blood|February 28, 2002
Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysisBeate Gleissner, Nicola Gökbuget, Claus R Bartram, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2012
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trialAnn-Lii Cheng, Zhongzhen Guan, Zhendong Chen, et al.
Journal of Hepatology|June 26, 2012
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trialJordi Bruix, Jean-Luc Raoul, Morris Sherman, et al.
Cancer|August 24, 2005
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrenceRichard A Larson, Eric L Sievers, Edward A Stadtmauer, et al.
The Lancet. Oncology|December 20, 2008
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialAnn-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Seminars in Oncology|June 26, 2002
Challenges in treating hematologic malignanciesDimitris Voliotis, Volker Diehl
Anti-Cancer Drugs|January 19, 2005
The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell linesMartina Heim, Mariam Scharifi, Jochen Zisowsky, et al.
Gastrointestinal Cancer Research : GCR|June 16, 2011
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B CirrhosisGhassan K Abou-Alfa, Dino Amadori, Armando Santoro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2004
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumorsDirk Strumberg, Heike Richly, Ralf A Hilger, et al.
Journal of Hepatology|January 17, 2012
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalysesJean-Luc Raoul, Jordi Bruix, Tim F Greten, et al.
Blood|February 28, 2002
Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysisBeate Gleissner, Nicola Gökbuget, Claus R Bartram, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2012
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trialAnn-Lii Cheng, Zhongzhen Guan, Zhendong Chen, et al.
Journal of Hepatology|June 26, 2012
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trialJordi Bruix, Jean-Luc Raoul, Morris Sherman, et al.
Cancer|August 24, 2005
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrenceRichard A Larson, Eric L Sievers, Edward A Stadtmauer, et al.
The Lancet. Oncology|December 20, 2008
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialAnn-Lii Cheng, Yoon-Koo Kang, Zhendong Chen, et al.
Pageof 2